HealthLeap Taps Industry Veterans to Scale AI Platform for Patient Care

SAN FRANCISCO, CA – January 12, 2026 – HealthLeap, a company developing an artificial intelligence platform to help clinicians identify at-risk patients, has announced the appointment of three seasoned executives to its leadership team. The move signals a strategic shift from founder-led growth to a concerted effort to scale operations and solidify its market position in 2026. The new hires are intended to accelerate the adoption of HealthLeap's technology, which aims to solve the pervasive and costly problem of underdiagnosed conditions in hospitals.

The San Francisco-based firm, founded in 2022, has brought on Wayne Grodsky as Chief Commercial Officer, Michael Blumental as Chief Strategy Officer, and Tamir Shklaz as Chief Technology Officer. This expansion comes as HealthLeap reports significant momentum, including a seven-fold revenue increase over the past seven months and partnerships with over 20 hospitals.

"HealthLeap is at an inflection point," said Josiah Meyer, co-founder and CEO. "With this leadership team, we will continue to increase our product's impact per customer, we'll scale to support more hospitals, and expand our AI platform to multiple additional clinical use cases."

Bolstering Leadership for Aggressive Growth

The new executive team brings a formidable depth of experience in scaling healthcare and technology companies, a clear indicator of HealthLeap's ambitions. Wayne Grodsky, the new CCO, has over 35 years of experience in healthcare leadership. His track record includes helping drive four healthcare technology transactions totaling more than $4 billion since 2010. At previous companies like SmarterDx and SOC Telemed, he was instrumental in architecting commercial strategies that led to significant revenue growth and expanded market penetration. At HealthLeap, Grodsky will helm the sales, customer success, and marketing initiatives, tasked with converting the company's early traction into widespread adoption.

Joining him is Michael Blumental as Chief Strategy Officer, a leader known for scaling AI-driven healthcare companies. In a recent role at the conversational AI firm Hyro, she was pivotal in growing the company from zero customers to a trusted partner for over 45 healthcare systems. Her experience in identifying new market opportunities and forging strategic partnerships will be crucial as HealthLeap seeks to expand its platform beyond its initial focus.

On the technology front, new CTO Tamir Shklaz brings a founder's mindset and a history of building products for massive user bases. A three-time startup founder, Shklaz previously developed COVID-19 response tools in partnership with the South African presidency that reached over one million daily users and processed more than $1 billion in PPE requests. His expertise in building robust, scalable systems will be essential as HealthLeap's AI is deployed across more health systems, where reliability and performance are paramount.

AI as a Clinical Safety Net

HealthLeap's core mission is to function as an intelligent safety net for patients within the complex hospital environment. The company's AI platform continuously analyzes vast amounts of data within a hospital's Electronic Health Record (EHR) system to flag potential risks that overburdened clinical teams might miss. The primary use case has been identifying hospital-acquired malnutrition, a condition that is both common and consequential.

Research indicates that disease-related malnutrition affects as many as one in three patients during their hospital stay and is associated with a three to five times higher mortality rate. The economic burden is staggering, contributing to an estimated $300 billion in annual costs in the U.S. through longer hospital stays, higher readmission rates, and other complications. Traditional methods, such as manual chart reviews and nursing-administered screening tools, are often inconsistent and do not scale effectively across an entire patient population.

HealthLeap's system automates this process, screening every inpatient daily. In a co-authored, peer-reviewed retrospective study, the company's predictive model demonstrated superior performance metrics compared to the manual screening tools used in practice. By providing clinicians with timely, AI-powered signals, the platform allows them to intervene earlier. This proactive approach not only improves patient outcomes but also creates a significant financial upside for hospitals by ensuring proper documentation for reimbursement and reducing the downstream costs associated with complications.

From Startup to Scale-Up

Founded in 2022 by sibling duo Josiah and Jemima Meyer—a clinician who began building tools to help her colleagues—HealthLeap has moved quickly from concept to commercialization. The company, which raised a $1.1 million pre-seed round in early 2022, has demonstrated impressive early-stage growth. The claim of delivering a five-fold or greater annual return on investment for its hospital partners, achieved through a combination of increased revenue and cost savings, has been a powerful driver of its expansion.

This rapid, founder-led growth has established a strong foundation. Now, with a seasoned executive team, the company is poised to build a more formal and scalable commercial engine. The goal is to move beyond the initial 20+ hospital partnerships and establish HealthLeap as an indispensable tool for health systems nationwide. The company's vision extends far beyond malnutrition, with plans to apply its AI platform to other overlooked clinical risks that impact patient safety and hospital margins.

Navigating the Complexities of AI in Healthcare

Despite the promise, the path to integrating AI into clinical practice is fraught with challenges that HealthLeap's new leadership will need to navigate. A major hurdle across the industry is technical interoperability. AI tools must seamlessly integrate with a hospital's existing IT infrastructure, particularly the fragmented and often proprietary EHR systems, without disrupting clinical workflows. Clinician trust is another critical factor; the "black box" nature of some AI algorithms can breed skepticism, making transparency and explainability key to adoption.

Furthermore, the regulatory landscape is complex and evolving. The U.S. Food and Drug Administration (FDA) is actively developing frameworks for AI-enabled medical devices, emphasizing a Total Product Life Cycle approach that ensures safety and effectiveness from development through post-market surveillance. Companies like HealthLeap must also address significant ethical considerations, including data privacy and the potential for algorithmic bias, ensuring their models are trained on representative data to promote health equity rather than perpetuate disparities.

The appointment of executives with deep experience in healthcare technology, strategy, and engineering suggests HealthLeap is keenly aware of these obstacles. Their collective expertise will be vital in building a product that is not only technologically advanced but also trustworthy, compliant, and seamlessly integrated into the daily work of caring for patients.

As CEO Josiah Meyer articulated, the ultimate vision is transformative. "Imagine if every hospital could use real-time AI to spot overlooked risks impacting their patient populations and then leverage those insights to provide care that reduces the patients' length of stay, readmission rates, mortality rates, and more," he stated. "Our mission is to maximize the health outcomes of as many people as possible." With its newly expanded leadership, HealthLeap is now better equipped than ever to pursue that ambitious mission.